Purvi Parikh, MD
Allergy & Immunology · New York, NYNPI 1629212592
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Genentech USA, Inc. at 25.8% of the total. Among allergy & immunology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $880.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$47K
- AstraZeneca$40K
- GSK$22K
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- Novartis$20K
- Shire North American Group Inc$11K
- plus $23K from 10 others
Across 9 payments — averaging $1394.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
- AstraZeneca$3K
- Astrazeneca AB$2K
- Astrazeneca UK Limited$2K
What the payments were for
- Consulting fees$109,68560%
- Speaking & faculty fees$51,42028%
- Travel & lodging$16,7069%
- Food & beverage$5,2513%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 62 | $47,162 |
| AstraZeneca | 39 | $40,206 |
| GSK | 20 | $22,278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $20,304 |
| Novartis | 18 | $19,850 |
| Shire North American Group Inc | 15 | $10,791 |
| Modernatx, Inc. | 5 | $8,968 |
| Alk-abello, Inc | 7 | $4,065 |
| Sanofi | 10 | $4,019 |
| Boehringer Ingelheim | 1 | $2,050 |
| Teva Pharmaceuticals USA, Inc. | 1 | $1,680 |
| Gilead | 1 | $1,500 |
| Boston Scientific | 1 | $121 |
| AbbVie | 3 | $65 |
| Novo Nordisk | 1 | $16 |
| Biocryst US Sales Co., LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XOLAIR$51,928
- FASENRA$17,992
- HYQVIA$15,836
- AIRSUPRA$15,048
- Moderna Covid-19 Vaccine$8,745
- GLASSIA$7,160
- Odactra$3,750
- Ragwitek$3,750
- Grastek$3,750
- CUVITRU$2,558
- SPIRIVA$2,050
- DUPIXENT$1,966
- AirDuo RespiClick$1,680
- ArmonAir Digihaler$1,680
- ProAir Digihaler$1,680
- SYMBICORT$1,611
- Veklury$1,500
- ELUVIA$121
How this compares
$183,091 in reported general payments places this provider in the 95th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 31 | $133,248 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $21,341 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $20,997 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,394 |
| Spiriva RespimatTiotropium Bromide | 12 | $5,895 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $3,749 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,835 |
| Epinephrine | 14 | $2,362 |
| Azelastine Hcl | 110 | $2,195 |
| Montelukast Sodium | 188 | $1,620 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,391 |
| Fluticasone Propionate | 91 | $1,242 |
| Mometasone Furoate | 21 | $926 |
| Levocetirizine Dihydrochloride | 19 | $164 |
| Ammonium Lactate | 11 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta | $22,278 | $42,33870 claims |
| AstraZenecaSymbicort | $40,206 | $6,39418 claims |
| Boehringer IngelheimSpiriva Respimat | $2,050 | $5,89512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in New York
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$946K
- Richard InselNew York$269K
- Arthur LubitzNew York$165K
- Ama AlexisNew York$120K
- Boyan HadjievNew York$97K
- Charlotte Cunningham-RundlesNew York$95K
- Paula BusseNew York$95K
- Hale YarmohammadiNew York$71K
- Joyce YuNew York$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.